DiaMedica Therapeutics Inc. Common Stock (DMAC)
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for neurological and kidney diseases. It leverages its proprietary DM200 monoclonal antibody platform to target complement-mediated diseases, aiming to address unmet medical needs in stroke, neurodegeneration, and kidney disorders.
Company News
DiaMedica (DMAC) rises 10% as it doses the first patient in the relaunch of its pivotal study evaluating the lead candidate, DM199, to treat acute ischemic stroke.
Upgrades For DiaMedica Therapeutics Inc (NASDAQ:DMAC), Oppenheimer upgraded the previous rating of Perform to Outperform. In the first quarter, DiaMedica Therapeutics showed an EPS of $0.20, compared to $0.13 from the year-ago quarter. At the moment, the stock has a 52-week-high of $4.05 and a 52-week-low of $1.12. DiaMedica Therapeutics closed a...
Looking for penny stocks on Reddit? Check these 5 out The post Penny Stocks to Buy Now? 5 Reddit Stocks To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.